Back to News
Market Impact: 0.4
Satellos Gets FDA Clearance For Forazapadin In FSHD; Phase 2 Study Planned
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
Satellos Bioscience announced that the FDA cleared its Investigational New Drug application for forazapadin in facioscapulohumeral muscular dystrophy (FSHD). The clearance enables clinical development of the investigational therapy and is a meaningful regulatory milestone for the company, though clinical efficacy and commercialization risks remain.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.55
More News
- Nvidia's CEO turmoil gives newly empowered Democrats fresh ammunition in pursuit of oversight
- Paraguay raids ex-president’s home: Why a bank crash brought down Pena
- Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval
- UniCredit CEO Plots Commerzbank Governance Overhaul
- Bon Secours affiliate sweetens bid for Surgery Partners to up to $6 billion
- EU Plans Crackdown on Addictive Social Media and AI Bot Features